ISPOR Webinar – Delivering Evidence-Based Access in Rare Diseases: The Challenges in SMA – April 5th
Rare diseases like spinal muscular atrophy (SMA) pose specific challenges for HTA approval, especially regarding data gaps resulting from small [...]
Massachusetts to Pay for Zolgensma on One Condition: It Must Work
Massachusetts' Medicaid program, MassHealth, has inked a conditional deal for Novartis' $2 million one-time spinal muscular atrophy (SMA) gene therapy, [...]
Advertisement
